LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) -- In a closely watched national class action involving allegations of UnitedHealthcare's predatory practices and Medicare Advantage fraud, U.S. District Judge Monica Ramirez Almadani wrote in her March 28, 2025 order: "This Court does not minimize the seriousness of the allegations in the Complaint or the grave issues in addressing vulnerable populations' access to healthcare." While the district court granted UnitedHealth's motion to dismiss solely on "preemptio ...

Core Viewpoint - UnitedHealth Group is currently under investigation by the Department of Justice for potential civil fraud related to its Medicare Advantage plans, which has led to a decline in its stock price [1][2][4]. Group 1: Investigation Details - The investigation focuses on how UnitedHealth records diagnoses that result in additional payments for its Medicare Advantage plans [2][7]. - A federal criminal health care-fraud unit is examining the company's practices involving doctors and nurses in gathering diagnoses to enhance payments [4]. - UnitedHealth has stated it is cooperating with federal investigators and has a history of responsible conduct and compliance [1][4]. Group 2: Business Overview - UnitedHealth's UnitedHealthcare division is the largest provider of Medicare Advantage plans, covering over 8 million individuals [3][4]. - The company generated more than $400 billion in revenue last year, ranking as the third-largest company in the Fortune 500 [5]. - The company also operates a growing Optum business that provides care and technology support [5]. Group 3: Stock Performance - UnitedHealth's stock price has decreased significantly, dropping 54% from its all-time high of over $630, with a recent price of $287.39 [5][8]. - The decline in stock value has been exacerbated by a spike in healthcare usage and a subsequent cut in the company's forecast earlier this year [8]. - The company is set to report its second-quarter results next Tuesday, which may further impact stock performance [8].

Core Insights - UnitedHealth Group Incorporated (UNH) is under investigation by the U.S. Department of Justice regarding its Medicare Advantage billing practices, specifically for potentially inflating diagnoses to receive higher payments from Medicare [1][3][8] - The investigation focuses on the HouseCalls program, where nurses visited patients at home and allegedly recorded diagnoses that led to additional payments, raising concerns about healthcare fraud [2][3] - As the largest player in the Medicare Advantage market, a criminal probe could have significant implications for UnitedHealth, including billions in federal payments and its overall business model [3][4] Company Performance - UnitedHealth has denied any wrongdoing, asserting that its practices comply with federal guidelines, but faces challenges amid rising medical costs and has withdrawn its 2025 earnings guidance [4][8] - The stock of UnitedHealth has declined by 40.2% year-to-date, compared to a 31.1% decline in the industry [7] - The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is projected at $21.85 per share, indicating a 21% decrease from the previous year [11] Industry Context - Other insurers, such as Molina Healthcare and Centene Corporation, are also struggling with rising medical costs, leading to reduced earnings guidance and financial outlooks [5][6] - Molina Healthcare has adjusted its 2025 earnings per share forecast down to between $21.50 and $22.50, while Centene Corporation has pulled its financial outlook due to higher medical costs [5][6]